LP
TCRX icon

LMR Partners’s TScan Therapeutics TCRX Stock Holding History

LMR Partners’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-71,800
Closed -$218K – 1632
2024
Q4 		$218K Hold
71,800
– – ﹤0.01% 945
2024
Q3 		$358K Sell
71,800
-593,729
-89% -$3.58M ﹤0.01% 883
2024
Q2 		$3.89M Buy
+665,529
New +$5.24M 0.03% 387

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

LMR Partners's TCRX Position: Q1 2025 in Review

LMR Partners sold out of TScan Therapeutics (TCRX) in Q1 2025, closing a stake of 71,800 shares — an estimated $218K sold.

LMR Partners first reported a position in TCRX in Q2 2024 and held it in 3 quarters. The position peaked at $3.89M in Q2 2024. 92 funds tracked by Wall St. Rank hold TCRX as of Q1 2025.

  • LMR Partners reported no remaining TScan Therapeutics position as of Q1 2025 after selling out during the quarter.
  • LMR Partners sold 71,800 TScan Therapeutics shares in Q1 2025, an estimated $218K.
  • LMR Partners first reported a position in TScan Therapeutics in Q2 2024 and held it in 3 quarters.
  • LMR Partners's TScan Therapeutics position peaked at $3.89M in Q2 2024.
  • 92 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2025.

Based on LMR Partners's 13F filing for Q1 2025, filed 15 May 2025.